Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Adaptimmune Therapeutics plc. (2/27/19). "Press Release: CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update". Philadeliphia, PA & Oxford.

Organisations Organisation Adaptimmune Therapeutics plc (Nasdaq: ADAP)
  Group Adaptimmune (Group)
  Organisation 2 M. D. Anderson Cancer Center
  Group University of Texas System
Products Product MAGE-A10 SPEAR™ T-cell therapy
  Product 2 MAGE-A4 SPEAR™ T-cell therapy
Persons Person Noble, James (Adaptimmune 201909– Non-Executive Director before CEO before MediGene + Avidex)
  Person 2 Amado, Rafael G. (Allogene 201909– EVP RnD + CMO before Adaptimmune + GSK + Amgen + UCLA)
     


   
Record changed: 2019-07-30

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Adaptimmune (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top